ADAMTS-13 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ADAMTS-13 (UniProt Q76LX8), HEK293-expressed vWF-cleaving protease for activity assays, inhibitor IC50 determination, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-ADAMTS13

In stock

SKU
REC-ADAMTS13
$498.00

Target Overview

ADAMTS-13 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 13; UniProt Q76LX8) is a secreted zinc-dependent metalloprotease encoded by the ADAMTS13 gene. The full-length human protein spans 1,427 amino acids and is produced endogenously in hepatic stellate cells and endothelial cells. Its defining biochemical function is the proteolytic cleavage of ultra-large von Willebrand factor (vWF) multimers at the Tyr1605–Met1606 bond within the vWF A2 domain, thereby reducing multimer size and limiting platelet thrombus formation under high shear stress. This recombinant is expressed in HEK293 cells, a mammalian host that supports the N-linked glycosylation and pro-domain processing characteristic of the native secreted form — features that are critical for substrate recognition and full enzymatic activity in biochemical assays. HEK293-derived ADAMTS-13 is therefore the preferred format for researchers requiring physiologically representative activity in vWF cleavage experiments, inhibitor dose–response measurements, and FRETS-vWF73 fluorogenic substrate assays. Researchers use this recombinant for several experimental purposes: establishing reference enzyme activity curves in ADAMTS-13-specific substrate cleavage assays, benchmarking inhibitory autoantibody titres from patient-derived plasma, and confirming assay linearity in ELISA-based activity kits. It also serves as a reliable positive control antigen for Western blot and immunohistochemistry validation of anti-ADAMTS-13 antibodies. Researchers requiring an antibody to pair with this recombinant for orthogonal validation experiments can use the matched Triple Point Biologics anti-ADAMTS-13 antibody (RP-ADAMTS13), cross-referenced on this product page. Sequence length: 1,427 amino acids. Expression host: HEK293. UniProt accession: Q76LX8. For research use only.

Background

ADAMTS-13 is the sole physiological protease responsible for size-regulating vWF multimers in the circulation. By cleaving the Tyr1605–Met1606 peptide bond within the mechanosensitive A2 domain of vWF — a bond exposed only under shear stress — ADAMTS-13 sets an upper size limit on circulating multimers and thereby calibrates the threshold for platelet plug formation. Severe deficiency of ADAMTS-13, whether inherited or acquired through inhibitory autoantibodies, results in accumulation of ultra-large vWF multimers and is the mechanistic basis of thrombotic thrombocytopenic purpura (TTP), a condition studied extensively in published research using recombinant ADAMTS-13 as the reference enzyme. Inherited (congenital) deficiency, known as Upshaw-Schulman Syndrome (USS), is caused by biallelic loss-of-function mutations across the ADAMTS13 gene. A 2026 mutation-spectrum study by Poznyakova et al. (PMID 42196618) characterised pathogenic variants in Russian USS patients, illustrating the continued need for reference recombinant protein in functional complementation and mutation-effect assays. Beyond TTP, ADAMTS-13 activity and gene polymorphisms have been investigated as research variables in thromboinflammatory and vascular contexts. Wrona et al. (PMID 42194965) examined ADAMTS13 polymorphisms in relation to coronary artery disease risk and long-term survival profiles, while Šantić et al. (PMID 42298010) characterised thromboinflammatory activation pathways in inflammatory bowel disease, a setting where vWF–ADAMTS-13 axis dysregulation has been described. ADAMTS-13 activity has also been studied in the context of complement-mediated thrombotic microangiopathy (TMA), where distinguishing primary TTP from secondary TMA has diagnostic and research implications (Yang et al., PMID 42259390). Separately, ADAMTS13 has been identified as a component of multi-gene plasma signatures under investigation for risk stratification in hypertensive intracerebral hemorrhage (Gao et al., PMID 42218946), underscoring its broader relevance as a research biomarker beyond classical thrombotic disease. In laboratory settings, recombinant ADAMTS-13 is used to generate activity standard curves for FRETS-vWF73 and collagen-binding substrate assays, to characterise inhibitory antibodies from patient plasma, and to test candidate small-molecule modulators in enzyme inhibition formats. The HEK293-expressed form is preferred in these experiments because its glycosylation profile and domain folding closely reflect the endogenous secreted protease. Researchers investigating structure–activity relationships or generating antibodies against specific ADAMTS-13 domains also use this recombinant as an immunogen and blot standard.

Applications

  • vWF multimer cleavage activity assay using FRETS-vWF73 fluorogenic substrate
  • Inhibitor IC50 determination for small-molecule or antibody-based ADAMTS-13 inhibitors
  • Inhibitory autoantibody characterisation from patient plasma by enzyme neutralisation assay
  • Activity standard curve generation for ELISA-based ADAMTS-13 activity kits
  • Western blot positive control for anti-ADAMTS-13 antibody validation (pairs with RP-ADAMTS13)
  • Immunogen for raising or validating anti-ADAMTS-13 antibodies against the native secreted form
  • Functional complementation assay for structure–function studies of ADAMTS13 missense variants
  • Substrate competition and kinetics assay under recombinant shear-stress-mimicking conditions

References

  1. Šantić R et al. Molecular determinants of thromboinflammatory activation in inflammatory bowel disease. J Mol Med (Berl). 2026. doi:10.1007/s00109-026-02693-7 PMID: 42298010
  2. Yang X et al. Multimodal Management of Anti-GBM Disease Complicated by Secondary Complement-Mediated Thrombotic Microangiopathy in a Patient Intolerant to Plasma Exchange: A Case Report. Ther Apher Dial. 2026. doi:10.1002/1744-9987.70172 PMID: 42259390
  3. Gao Z et al. Identification and multicenter validation of a 4-gene plasma signature for early recognition and risk assessment in hypertensive intracerebral hemorrhage. Genomics. 2026. doi:10.1016/j.ygeno.2026.111268 PMID: 42218946
  4. Poznyakova J et al. Mutation Spectrum of ADAMTS13 Gene in Patients with Upshaw-Schulman Syndrome (USS) in Russia. Int J Mol Sci. 2026. doi:10.3390/ijms27104643 PMID: 42196618
  5. Wrona J et al. ADAMTS13 Gene Polymorphisms and Coronary Artery Disease Risk, Long-Term Survival, and Risk Factor Profile. Genes (Basel). 2026. doi:10.3390/genes17050508 PMID: 42194965

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What is the expected molecular weight of recombinant ADAMTS-13 on SDS-PAGE or Western blot?

The full-length human ADAMTS-13 polypeptide (1,427 aa) has a predicted molecular weight of ~145 kDa, but the HEK293-expressed recombinant runs at approximately 160–180 kDa under reducing SDS-PAGE conditions due to N-linked glycosylation at multiple sites. This glycosylated form is consistent with the endogenous secreted enzyme. If you are running a non-reducing gel, expect potential disulfide-linked migration artifacts. For Western blot validation using the matched rabbit polyclonal RP-ADAMTS13, the 160–180 kDa band is the expected positive control signal.

What processing or isoform state is this recombinant ADAMTS-13 — pro-form or mature cleaved enzyme?

This recombinant is expressed in HEK293 cells and undergoes pro-domain removal during secretion, yielding the mature, active form characteristic of the endogenously processed enzyme. It is not a pro-enzyme requiring exogenous activation. The furin-like convertase cleavage that removes the pro-domain occurs intracellularly in HEK293 cells, paralleling the native processing pathway. Researchers designing inhibitor screens or substrate cleavage assays should note they are working with the constitutively active mature metalloprotease, not a zymogen, which eliminates the need for an activation step.

What substrate does recombinant ADAMTS-13 cleave and at which bond?

ADAMTS-13 cleaves ultra-large von Willebrand factor (vWF) multimers at the Tyr1605–Met1606 peptide bond within the vWF A2 domain. For in vitro activity assays, the standard minimal substrate is the 73-amino acid peptide FRETS-vWF73, a fluorescence-resonance energy transfer peptide spanning the A2 domain cleavage site. Cleavage of FRETS-vWF73 generates a measurable increase in fluorescence (excitation ~340 nm, emission ~440 nm). Full-length vWF or recombinant vWF A2 domain fragments are also used for more physiological multimer reduction assays under defined shear conditions.

What buffer conditions does recombinant ADAMTS-13 need for maximum activity in a cleavage assay?

The storage buffer is 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂. For activity assays, ADAMTS-13 is active across pH 7.0–8.0, with optimal activity near pH 7.5. Maintain 5 mM CaCl₂ in the assay buffer; as a zinc-dependent metalloprotease its activity is sensitive to metal chelators — avoid EDTA or EGTA entirely. 1 mM DTT or 1 mM β-mercaptoethanol is tolerated and can improve stability over long incubations. BSA (0.1–0.5%) in the assay buffer reduces nonspecific adsorption to tube walls at low enzyme concentrations.

What starting concentration of recombinant ADAMTS-13 should I use for a FRETS-vWF73 fluorescence activity assay?

For a standard FRETS-vWF73 assay, a useful starting point is 50–200 nM recombinant ADAMTS-13 with 1–2 µM FRETS-vWF73 substrate in 50 mM Tris-HCl pH 7.5, 5 mM CaCl₂, 0.1% BSA at 37°C. Under these conditions, cleavage is typically linear for 30–60 minutes, allowing reliable initial velocity measurements. For IC₅₀ determination of inhibitors, titrate enzyme to the lowest concentration still giving a robust, reproducible signal — typically 25–50 nM — to avoid substrate depletion artifacts. Confirm linearity with respect to enzyme concentration before committing to a full inhibitor panel.

Can I use recombinant ADAMTS-13 as a positive control for Western blot with the RP-ADAMTS13 antibody?

Yes, and this is a validated use case. Load 50–100 ng of this recombinant per lane on a standard SDS-PAGE gel alongside your cell lysate or plasma samples. The matched rabbit polyclonal RP-ADAMTS13 (SKU: RP-ADAMTS13) was raised against an ADAMTS-13 fragment and is guaranteed compatible with this recombinant for Western blot positive control applications. You will see a clean band at approximately 160–180 kDa. This pairing also serves directly for antibody lot validation, ensuring your RP-ADAMTS13 antibody performs before committing it to experimental samples.

How much recombinant ADAMTS-13 should I load for a Western blot positive control lane?

50–100 ng per lane is the recommended loading range when using RP-ADAMTS13 at a 1:1,000–1:2,000 dilution. At 50 ng you should see a strong, unambiguous band at ~160–180 kDa without obscuring nearby molecular weight markers. If you are troubleshooting a new membrane or detection system, run a small titration: 25, 50, 100, and 200 ng in parallel. The recombinant is >90% pure by SDS-PAGE, so the dominant band will be ADAMTS-13 with minimal background, making it straightforward to set exposure times for your experimental lanes.

How should I dilute, aliquot, and store recombinant ADAMTS-13 to preserve activity long-term?

The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂ and is stable at −20°C for at least 12 months when stored as single-use aliquots. Repeated freeze-thaw cycles measurably reduce metalloprotease activity — prepare working aliquots at the volume you consume in one experiment and avoid returning thawed material to the freezer. For dilutions below ~10 nM, add carrier protein (0.1–0.5% BSA) to prevent adsorptive losses to tube surfaces. Do not dilute into EDTA-containing buffers; zinc chelation will inactivate the enzyme irreversibly.

Validation imagery coming soon

Western blot validation figures for REC-ADAMTS13 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →